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Cancer Cells and the Tumor
Microenvironment Modulate TRAIL
Signaling: Implications for TRAIL
Receptor Targeted Therapy
Margot de Looff, Steven de Jong and Frank A. E. Kruyt*
Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands
Tumor necrosis factor (TNF) related apoptosis-inducing ligand (TRAIL) signaling is far
more complex than initially anticipated and can lead to either anti- or protumorigenic
effects, hampering the successful clinical use of therapeutic TRAIL receptor agonists.
Cell autonomous resistance mechanisms have been identified in addition to paracrine
factors that can modulate apoptosis sensitivity. The tumor microenvironment (TME),
consisting of cellular and non-cellular components, is a source for multiple signals that
are able to modulate TRAIL signaling in tumor and stromal cells. Particularly immune
effector cells, also part of the TME, employ the TRAIL/TRAIL-R system whereby cell
surface expressed TRAIL can activate apoptosis via TRAIL receptors on tumor cells,
which is part of tumor immune surveillance. In this review we aim to dissect the
impact of the TME on signaling induced by endogenous and exogenous/therapeutic
TRAIL, thereby distinguishing different components of the TME such as immune effector
cells, neutrophils, macrophages, and non-hematopoietic stromal cells. In addition, also
non-cellular biochemical and biophysical properties of the TME are considered including
mechanical stress, acidity, hypoxia, and glucose deprivation. Available literature thus far
indicates that tumor-TME interactions are complex and often bidirectional leading to
tumor-enhancing or tumor-reducing effects in a tumor model- and tumor type-dependent
fashion. Multiple signals originating from different components of the TME simultaneously
affect TRAIL receptor signaling. We conclude that in order to unleash the full clinical
potential of TRAIL receptor agonists it will be necessary to increase our understanding of
the contribution of different TME components on outcome of therapeutic TRAIL receptor
activation in order to identify the most critical mechanism responsible for resistance,
allowing the design of effective combination treatments.
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INTRODUCTION
TRAIL receptors (TRAIL-Rs) are able to selectively induce apoptosis in cancer cells and are
considered promising therapeutic targets. However, in clinical studies the efficacy of TRAIL-R
agonists has been rather disappointing thus far. Novel formulations of TRAIL-R agonists
able to more efficiently cluster and activate TRAIL-Rs have been developed and may lead to
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better therapeutic response (1). However, the fact that TRAIL
signaling is more complex than initially thought hampers
the successful use of these receptor agonists. For example,
TRAIL signaling was found to have protumorigenic effects in
apoptosis resistant tumor cells leading to unwanted stimulation
of proliferation and metastatic spread (2, 3). In addition to
cell autonomous mechanisms responsible for TRAIL resistance
and non-canonical signaling also cell extrinsic signals have been
identified that modulate the TRAIL pathway.
Tumors resemble organs as they contain heterogeneous
(tumor) cell populations with distinct differentiation status
and cellular functions such as blood vessels, immune cells,
and fibroblasts. The non-cancer cell compartment of a tumor
is known as the TME and has been irrefutably demonstrated
to play a key role in tumorigenesis, tumor progression, and
therapeutic efficacy (4–6). Importantly, dynamic changes
in the TME accompany tumor progression and therapeutic
resistance and strategies aimed at reprogramming the
cellular TME toward an antitumor state provide a promising
therapeutic approach.
In this review, we focus on the impact of the TME on
the outcome of TRAIL signaling in tumor cells. This includes
endogenous TRAIL/TRAIL-R signaling being part of immune
effector cell functioning and tumor immune surveillance
as well as modulation of therapeutic efficacy of TRAIL-
R agonists by bidirectional tumor/stroma cell signaling and
specific biochemical and biophysical properties characteristic
of the TME. The nature and implications of these pleiotropic
interactions are highlighted and consequences for the efficacy of
TRAIL-based therapy are discussed.
TRAIL RECEPTOR TARGETED
CANCER THERAPY
TRAIL receptor agonists have been developed to induce
apoptosis selectively in tumor cells, while preserving normal cells
(7–9). Depending on their binding characteristics these agonists
bind to both, or either one of the apoptosis-inducing receptors
TRAIL-R1 and -R2. These receptors share a death effector
domain required for ligand-induced formation of the death-
inducing signaling complex (DISC) consisting of FAS-associated
death domain (FADD) and procaspase-8, leading to caspase-8
activation and subsequent caspases-dependent apoptosis. This so
called extrinsic apoptotic pathway is connected to the intrinsic or
mitochondrial apoptotic pathway via the BCL2-family member
BID. Caspase-8-dependent BID cleavage produces truncated
(t)BID that via interactions with proapoptotic BAX and BAK
disrupt mitochondrial membranes resulting in the release
of proapoptotic factors such as cytochrome C, a co-factor
for apoptosome formation resulting in activation of initiator
procaspase-9 (10). TRAIL-R agonists are usually designed to have
reduced binding affinity for decoy TRAIL-Rs, named TRAIL-
R3 and TRAIL-R4. These membrane receptors have a TRAIL-
binding domain but lack cytoplasmic domains required for
apoptosis activation, whereas a fifth TRAIL binding protein
named osteoprotegerin (OPG) is soluble and also able to
sequester TRAIL, thus suppressing TRAIL-R1/R2-dependent
apoptosis (11).
In spite of the anticipated powerful therapeutic potential of
TRAIL-R agonists, apoptosis resistance is often encountered
in cell culture and in vivo cancer models, providing an
explanation for disappointing results in clinical studies (12–14).
Importantly, TRAIL-Rs were found to induce non-canonical
signaling involving activation of pro-inflammatory, pro-
survival, and proliferation pathways leading to protumorigenic
and even metastasis-promoting effects (2, 3). Non-canonical
signaling is predominantly mediated by TRAIL-R1 and -
R2 and involves the formation of a secondary signaling
complex consisting of among others, receptor-interacting
serine/threonine protein kinase 1(RIPK1), Tumor necrosis factor
(TNF) receptor associated factor 2 (TRAF2) and TNF receptor
associated death domain (TRADD) (2, 15). Subsequently, this
signaling complex is able to activate various protumorigenic
pathways including IκB/NF-κB, MAPK/ERK, STAT3, PI3K, Akt,
JAK2, and Src.
TRAIL resistance has been often regarded as a tumor-
autonomous property and various apoptosis resistance
mechanisms have been identified such as absence of caspase-8
or elevated expression of various apoptosis blocking proteins
including cellular FLICE-like inhibitory protein (cFLIP), X-
linked inhibitor of apoptosis proteins (XIAPs), antiapoptotic
BCL-2 family members, which have been extensively reviewed
elsewhere (11, 16, 17). However, cell extrinsic signals derived
from the TME can also modulate TRAIL apoptotic signaling.
Current evidence for such interactions and consequences for
therapy are discussed below.
THE TUMOR MICROENVIRONMENT
The TME consists of cellular components including various
myeloid and lymphoid cells, fibroblasts and endothelial
cells that via direct interactions or biochemical cues (auto-,
para-, and endocrine signaling) communicate with tumor
cells. In addition, a non-cellular TME can be distinguished
consisting of extracellular matrix (ECM), mechanical pressure
and tumorigenic conditions like acidity, hypoglycemia and
hypoxia that impact tumor behavior (18). The fate of a tumor
is dependent on dynamic properties of the TME ranging from
anti- to protumorigenic. The antitumorigenic TME encompasses
normal fibroblasts (NF), dendritic cells (DCs), natural killer
(NK) cells, cytotoxic T cells, and M1-activated tumor-associated
macrophages (TAMs) involving the activity of proinflammatory
cytokines. The protumorigenic TME, on the other hand, is
associated with immune suppressive effects of M2-activated
TAMs involving production of anti-inflammatory cytokines,
myeloid-derived suppressor cells (MDSC), regulatory T (Treg)
cells and B cells, cancer-associated fibroblasts (CAFs) producing
aberrant ECM, and TIE2-expressing monocytes and mast
cells with angiogenesis stimulatory activity. Similar to TAMs,
neutrophils and T helper (Th) cells can have both pro- and
antitumorigenic activity depending on tumor and immune
context. For a comprehensive review of the cellular TME and
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impact on tumor progression and tumor cell dissemination see
Quail and Joyce (18).
REGULATION OF ENDOGENOUS TRAIL BY
THE TME
Physiological Role of TRAIL
TRAIL has been identified as a key mediator of the innate
immune response including a role in tumor immune
surveillance. Endogenous TRAIL, encoded by the TNFSF10
gene, is a 281 amino acid (aa), 33 kDa type II transmembrane
protein with a small intracellular domain of 17 aa (8, 19).
The extracellular domain of TRAIL can be cleaved by cysteine
proteases to produce soluble TRAIL (∼20 kD). TRAIL
and TRAIL-Rs are expressed in various tissues including
immunogenic organs like spleen and thymus. Indeed, a variety
of innate and adaptive immune cells express TRAIL such as
monocytes, macrophages, DCs, NK cells, and cytotoxic T cells
(CTLs) (20, 21). TRAIL and TRAIL-R expression is regulated by a
variety of factors depending on the cellular context. For example,
IFNs can activate transcription of TRAIL via the IRF1/STAT3
complex. Furthermore, TRAIL and TRAIL-R transcription is
regulated by stress-induced factors like nuclear factor of activated
T-cells (NFAT), Forkhead Box (FOX) proteins, NF-κβ, C/EBP
homologous protein, activator protein 1 (AP1), and p53 in both
immune and transformed cells (22, 23).TRAIL signaling can
regulate adaptive immune cells by removing aberrantly activated
T effector cells maintaining T cell homeostasis. For example
CD8+ T cell memory expansion is regulated by CD4+ T helper
(Th1) cells via TRAIL dependent apoptosis (24).
Besides being a cytotoxic effector of immune cells in
infectious diseases, TRAIL expressing immune cells also play
a role in tumor suppression, although not in a consistent
way (20, 25). For example, in mice having only one Trail-R,
Trail-R knockout had no effect on incidence of spontaneous
tumor development in siblings obtained from hybrid APC–/–
(intestinal adenomas) or p53–/– (lymphomas) mice (26), whereas
siblings of Trail–/– and P53+/– mice developed more sarcomas
and lymphomas (27). Further, monitoring carcinogen-induced
tumorigenesis in Trail–/– mice vs. controls demonstrated a
tumor suppressive effect of Trail (28). Intriguingly, in this
study no differences were detected on primary tumor formation,
however, Trail-R deficient mice showed enhanced metastatic
spread to lymph nodes suggesting particularly Trail-mediated
suppressive effects on disseminating tumor cells (29). Thus,
the TRAIL/TRAIL-R system is predominantly part of immune
effector cell functioning and has variable effects on tumor
progression and may differentially impact distinct stages of
tumor development.
Immune Effector Cells
Immune effector cells from both the innate and adaptive
immune system are part of the TME and elicit both pro-
and antitumorigenic responses. Various immune effector cells,
described in more detail below, express TRAIL allowing them to
bind and activate TRAIL-Rs on tumor cells.
NK cells are the main effector cells from the innate
immune response and eliminate aberrant tumor cells by
granule release (perforin/granzyme) dependent toxicity and
via membrane receptor interactions involving FasL, TNFα,
and TRAIL depending on their differentiation and activation
status (30, 31). In syngeneic cancer mice models activation
of NK cells by IL12 resulted in IFNγ production, which was
essential for further activation and augmenting TRAIL surface
expression responsible for anti-metastatic activity in TRAIL
sensitive tumors (31, 32). Depletion of each single component
of the NK cell-IFNγ-TRAIL axis promoted tumor growth
in a chemical-induced murine sarcoma model illustrating its
importance in antitumor responses (33). Moreover, activated NK
cells employ membrane bound TRAIL, but not soluble TRAIL, to
support their cytotoxicity against neuroblastoma cells, which are
normally resistant to soluble TRAIL (34).
Cytotoxic T-cells (CTLs) are the main effector cells of
the acquired immune response and also make use of the
TRAIL/TRAIL-R system to induce apoptosis in target cells. For
example, expression of TRAIL onCTLs can be enhanced by T-cell
receptor-mediated interaction with TRAIL-R-expressing human
non-small cell lung cancer (NSCLC) cells. IFNα significantly
enhanced TRAIL expression on CTLs and effectively triggered
apoptosis in TRAIL sensitive NSCLC cells in vitro. Antitumor
activity was also seen in immune–deficient mice implanted with
TRAIL sensitive NSCLC cells in which intratumoral injection
of autologous activated CTLs resulted in TRAIL-R2-dependent
tumor cell death (35).
DCs play a role in both innate and adaptive immune responses
by communicating to both immune effector cells and presenting
antigens to T cells. Cytotoxic DCs can be activated by IFNα or
IFNγ displaying antitumor activity adopting the TRAIL/TRAIL-
R system (36, 37).
The activity of the immune effector cells can be counteracted
by immunosuppressive Tregs. Tregs secrete a range of soluble
factors such as TGFβ, IL10, and IL35, which can suppress effector
T cell expansion and cytokine secretion (IFNγ, TNFα) (38).
Tumor infiltrating Tregs repress antitumor immune responses by
inhibiting the cytotoxic activity of CTLs, NK cells, and DCs. In
rodent colon cancer models Tregs were able to inhibit cell death
induced by TRAIL expressing DCs. Innate immune response
activation by Mycobacterium Bacillus Calmette-Guérin (BCG)
combined with cyclophosphamide treatment depleted Tregs and
potentiated DC-induced tumor cell killing (39). Orthotopic
implantation of TRAIL resistant murine pancreatic cancer cells
in either WT or TRAIL knockout mice resulted in smaller
tumors in TRAIL knockout mice. Tumor growth in WT mice
was associated with increased tumor infiltrating CD4+ Treg cells
that was further enhanced by treating mice with recombinant
TRAIL, which also enhanced tumor growth. Although the
underlying mechanism of TRAIL-dependent tumor infiltration
was not addressed, it is likely that TRAIL in the context
of resistant tumor cells potentiated the immune suppressive
effects of Treg cells resulting in enhanced tumor growth (40).
Notably, in mice Tregs can also directly eliminate CTLs via
TRAIL/TRAIL-R2-mediated apoptosis (41). On the other hand,
CTLs can produce cytokines that increase the sensitivity of
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tumor cells for TRAIL. Upon T-cell receptor activation CD8+
CTLs produced soluble IFNγ and TNFα, which increased the
susceptibility of neuroblastoma cells for TRAIL-induced caspase-
8 activation (42).
Tumor cells can counteract the activity of immune effector
cells by inhibiting TRAIL-induced apoptotic signaling. For
example, follicular lymphomas expressing CD40, an important
co-stimulatory receptor able to interact with ligand expressed
on germinal center CD4+ T-cell subpopulations, protected from
TRAIL-induced apoptosis by CTLs. CD40 activation induced
NF-κB leading to upregulation of antiapoptotic cFLIP and
Bcl-XL (43, 44).
Antitumor activity of TRAIL expressing DCs was reduced
by apoptotic tumor lysate derived from TRAIL sensitive murine
lymphomas. TRAIL expression could be partially restored both
in vitro and in vivo upon stimulation by IL15, or LPS leading
to prolonged TRAIL expression on DCs and antitumor activity.
On the other hand, while stimulating DCs, IL15 inactivated
STAT3 in lymphoma cells resulting in TRAIL resistance that
could be neutralized by combined treatment with the STAT3
inhibitor Cucurbitacin I leading to an overall effective therapeutic
response (45).
Activated TRAIL-Rs on tumor cells can also trigger a
counterattack and create an immune suppressive TME. TRAIL
resistant human colon cancer cells were found to release
microvesicles containing FAS and TRAIL that were also
detectable in plasma from patients. These microvesicles could
eliminate CTLs thus providing an immune escape mechanism
(46). Endogenous cell surface TRAIL on multiple myeloma cells
could eliminate osteoclasts and prevent bone formation thereby
facilitating metastatic lesions (47, 48). TRAIL-resistant gastric
carcinoma cells from primary and metastatic patients expressed
TRAIL and TRAIL-Rs, including TRAIL-R4. Interestingly, tumor
infiltrating lymphocytes (TIL) from patients with a primary
tumor hardly expressed TRAIL/TRAIL-Rs, whereas those from
metastatic patients showed high levels and displayed apoptosis.
This suggests that in metastatic lesions tumor cells can evade
immune surveillance by inducing TRAIL- mediated cell death of
TILs (49). Similarly TRAIL expressing colorectal cancer (CRC)
cells in patient samples were linked with apoptosis induction
in tumor infiltrating CD8+ T-cells via TRAIL-R1 providing an
immune escape mechanism (50).
Taken together, the TRAIL-dependent immune effector
function can be potentiated by various cytokines that can be
counteracted by Tregs. Particularly TRAIL resistant tumors,
but also sensitive tumor cells can respond by expressing or
secreting factors that inhibit immune effector cell-induced
apoptosis or even eradicate immune cells by TRAIL/TRAIL-R
dependent mechanisms.
Neutrophils and Macrophages
Neutrophils are an essential part of the innate immune system
and are the most abundant leukocytes in the blood. Similar to
monocytes that can differentiate into macrophages, neutrophils
possess phagocytic activity. They can migrate to sides of acute
inflammation as well as tumors where they can have both tumor
suppressive and supportive functions (51). Neutrophils and
monocytes both express TRAIL and target TRAIL-R expressing
tumor cells. In vitro experiments showed that IFNα exposure of
neutrophils/monocytes led to increased release of soluble TRAIL
resulting in apoptosis activation in TRAIL sensitive chronic
myeloid leukemia (CML) cells. Additionally, IFNα protected
both neutrophils and monocytes from leucine-zipper TRAIL
and soluble rhTRAIL induced apoptosis, which may be related
to absence or low levels of TRAIL-R1/R2 and high TRAIL-
R3 expression. Furthermore, melanoma patients treated with
IFNα showed increased soluble TRAIL serum levels indicating
in vivo relevance of this antitumorigenic mechanism (52). This
mechanism provides an explanation for treatment efficacy of
IFNα in CML and melanoma patients.
Peritumoral administration of granulocyte colony-stimulating
factor (G-CSF) has been reported to suppress murine mammary
adenocarcinoma progression in mice, which was not seen upon
in vitro exposure of tumor cells to this cytokine. G-CSF appeared
to increase the number of infiltrating neutrophils accompanied
with upregulation of death-inducing proteins including TRAIL
providing an explanation for antitumor activity (53).
In esophageal squamous cell carcinoma (ESCC) the presence
of IL17 producing cells was associated with a favorable prognosis.
IL17 stimulated ESCC-dependent secretion of neutrophil-
attracting chemokines and, moreover, enhanced their immune
effector function also characterized by TRAIL (54).
Another study found that cathepsin E expressed on immune
cells can cleave and activate endogenous cell surface TRAIL
on prostate and melanoma cells and enhance macrophage
infiltration leading to antitumor activity. Cathepsin E reduced
murine melanoma growth in mice, when compared to tumor
growth in cathepsin E knockout mice. This was accompanied
with increased tumor infiltration of activated macrophages and
apoptosis activation in tumor cells (55).
Macrophages were reported to secrete matrix
metallopeptidase 12 (MMP12) and stimulate TRAIL-dependent
apoptosis in tumor cells. MMP12 activity could be mimicked
by a recombinant C-terminal domain peptide, named SR20,
that could induce TRAIL-mediated apoptosis both in oncogenic
mutated KRAS and WT murine and human NSCLC cells as
demonstrated in vitro and in orthotopically implanted mice and
a KRAS-induced murine mouse model. In addition to protein
cleavage activity, SR20 translocated to the nucleus of these cells
leading to transcriptional upregulation of TRAIL and TRAIL-R1
mRNA and downregulation of antiapoptotic proteins that was
responsible for the observed tumor cell death (56).
Conversely, in addition to the TRAIL-dependent antitumor
activity of neutrophils and macrophages also protumorigenic
activity has been demonstrated involving the cooperative
action of various cytokines produced by tumor cells and
different immune cells. For example, in murine hepatocarcinoma
and melanoma mice models IL35 was found to polarize
neutrophils into a protumorigenic N2 state and enhance tumor
infiltration that was accompanied by downregulation of TRAIL
expression. This involved the concerted action of various
cytokines and immune cells cumulating in IL6/IL1β/IL17/G-CSF
induced STAT3-dependent downregulation of TRAIL expression
on neutrophils and simultaneous upregulation of MMP9
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together resulting in immune suppression and a proangiogenic
state (57, 58).
The MUC5AC glycoprotein expressed on pancreatic cancer
cells was required for tumor growth in vivo by suppressing
antitumor effects of neutrophils. MUC5AC was found to
suppress tumor secretion of the neutrophil attractant IL8 and,
moreover, MUC5AC blocked TRAIL-R mediated apoptosis of
tumor cells via an as yet unknown mechanism (59).
Summarizing, macrophages and neutrophils can eliminate
tumor cells via the TRAIL/TRAIL-R system that can be
potentiated or suppressed by various mechanisms involving
administrated or tumor-derived cytokines as well as tumor or
immune cell expressed activators or suppressors.
Non-hematopoietic Stromal Cells
Expression of TRAIL on stromal cells has been demonstrated
to be a favorable characteristic for patient survival (60).
Immunohistochemistry (IHC) studies of patient tissue arrays
demonstrated that increased TRAIL expression in the epithelium
and connective tissues of prostate and ovarian cancer is
associated with elongated recurrence free survival and favorable
overall survival, respectively. This effect was independent of
decreased TRAIL-R expression and increased cFLIP-L expression
in tumor cells (61, 62).
Mesenchymal stem cells (MSC) are derived from bone
marrow and can differentiate into various cell types including
osteoblasts and adipocytes and home to tumors making part
of the tumor stroma. Ex vivo exposure of human MSCs to
TNFα increased TRAIL expression. Subsequent infusion of these
hMSC in mice implanted with MDA-MB-231 breast cancer cells
inhibited tumor growth. Furthermore, co-culturing these hMSC
with several cancer cell lines resulted in apoptosis induction.
Interestingly, these dying tumor cells released DNA that acted as
damage-associated molecular patterns (DAMPs) that via a TLR3-
dependent NF-κβ feed forward loop further increased TRAIL
expression on hMSC, thereby potentiating their antitumor
activity (63). In follow up work TNFα-activated hMSC were also
found to produce IFNβ in response to released DNA/RNA from
apoptotic breast cancer cells further enhancing TRAIL expression
and potentiation of antitumor activity (64). Accordingly, this
feedforward loop of TRAIL-induced apoptosis was not seen in
apoptosis resistant breast cancer cells. Moreover, CAFs isolated
from breast cancer patients showed a similar increase in TRAIL
and IFNβ upon exposure to DNA.
Thus, bidirectional signaling between TRAIL sensitive tumor
cells and stromal cells can create a tumor-suppressive TME.
MODULATION OF EXOGENOUS TRAIL
RECEPTOR AGONIST ACTIVITY AND
THE TME
From a therapeutic standpoint pharmacological administration
of TRAIL-R agonists aims to mimic the function of TRAIL-
expressing immune effector cells. In this part the impact of
different components of the TME on the efficacy of exogenously
administrated TRAIL is highlighted.
Stromal Cells
Stromal cells express TRAIL decoy receptors and create a sink
for administrated recombinant TRAIL leading to suppression of
antitumor activity. OPG is predominantly secreted by osteoblasts
and functions as a paracrine survival factor in bone marrow TME
and has been implicated in TRAIL resistance. OPG protected
prostate cancer and multiple myeloma cells against TRAIL-
mediated cell death (65, 66). Bone marrow stromal cells from
breast cancer patients also produced sufficient OPG levels to
decrease TRAIL sensitivity of breast cancer cells providing a
mechanism for the occurrence of metastatic lesions in the
bone (67). OPG production can be enhanced by cytokines. For
example, IL1β increased OPG expression in both TRAIL sensitive
MDA-MB231 and resistant MCF7 cells. Gene silencing of OPG
enhanced apoptosis in MDA-MB231 cells, but not in MCF7 cells,
and a positive correlation was found between OPG levels and
TRAIL sensitivity (68). TRAIL variants have been developed
with reduced affinity for decoy receptors and demonstrated
superior antitumor activity in the presence of OPG producing
cells or recombinant OPG (69). Similarly, the expression of
TRAIL-R3/R4 on CAFs decreased the efficacy of TRAIL induced
apoptosis in tumor cells that could be bypassed by developed
TRAIL variants with reduced binding activity to these decoy
receptors (70).
Epidermal growth factor (EGF) could protect TRAIL sensitive
HEK293 and MDA-MB-231 tumor cells for apoptosis involving
Akt activation and inhibition of mitochondrial apoptosis (71).
On the other hand, in non-transformed MCF10A human
breast epithelial cells EGF sensitized for TRAIL-induced
apoptosis that was counteracted by TGFβ involving reduction
of DISC formation and activation of cytoprotective autophagy
(72). The differential activity of EGF in normal and tumor
cells illustrates differential wiring of TRAIL signaling upon
oncogenic transformation.
Cytokines exogenously added or produced by either tumor
or stromal cells can inhibit TRAIL-induced apoptosis in
tumor cells. TRAIL-sensitive ovarian cancer cells reverted to
resistant cells by exposure to IL8 that was associated with
downregulation of TRAIL-Rs (73). IL8 produced by tumor
cells or recombinant IL8 also was shown to suppress TRAIL-
induced apoptosis in prostate cancer cells by up-regulation of
the anti-apoptotic proteins cFLIP(S) and cFLIP(L) in a CXCR2
and NF-κB-dependent way. TRAIL as well as chemotherapy
could enhance IL8 expression leading to apoptosis resistance
and a CXCR2 antagonist sensitized for TRAIL providing a
therapeutic strategy (74). Primary cancer cells from breast,
colon, and lung carcinomas produce IL4 that protected tumor
cells for TRAIL-induced apoptosis by increasing expression of
a number of anti-apoptotic proteins including cFLIP, Bcl-XL,
and Bcl-2 (75). Metastatic melanoma cells endogenously express
proinflammatory TNFα and IL6 leading to constitutive NF-κB,
STAT3, and COX2 expression. Neutralizing antibodies against
these cytokines and genetic or pharmacological inhibition of the
downstream pathways resulted in sensitization for exogenous
TRAIL-induced apoptosis (76). TLR4 ligation on human lung
cancer cells and associated NF-κB activation reduced apoptotic
effects of TRAIL and, in addition, promoted the production
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of immunosuppressive cytokines TGFβ and IL8 together with
proangiogenic VEGF (77).
Ovarian cancer (OC) is commonly associated with peritoneal
ascites production and provides a unique TME for this
tumor type. A proportion of ascites samples taken from
OC patients could mediate resistance toward TRAIL-induced
apoptosis in a panel of OC cell lines in vitro (78). Further
research showed that malignant ascites leads to activation of
PI3K, Akt, ERK1/2, and ELK1 and up-regulating cFLIP(s)
and Mcl-1 and inhibition of TRAIL-induced caspase-dependent
apoptosis (79).
Co-culturing of multiple myeloma cells and HS5 stromal
cells attenuated TRAIL-induced cell death involving soluble
factors produced by the stromal cells. Antiapoptotic cFLIP was
identified as a mediator for resistance as silencing its expression
increased TRAIL sensitivity (80). In a follow up study stromal-
mediated resistance was found to involve NF-κB-dependent
cFLIP expression that could be prevented by the proteasome
inhibitor bortezomib that restored TRAIL sensitivity in tumor
cells without affecting stromal HS5 cells (81). Myoblasts secreting
platelet-derived growth factor BB (PDGF-BB) indirectly affected
TRAIL sensitivity by activating Hedgehog (Hh) signaling in
cholangiocarcinomas (CCA) thereby shifting the cells toward
TRAIL resistance. Inhibition of Hh signaling by cyclopamine
increased apoptosis in CCA cells in vitro and in a syngeneic
RAT CCA model resulting in tumor suppression (82). Co-
culturing of Wnt producing rat embryonic fibroblasts protected
TRAIL sensitive human pre-B leukemia cells for TRAIL-induced
apoptosis. Although the precise mechanism was not fully
elucidated inhibition of MEK1/ERK1/2 and NF-κB signaling
sensitized for TRAIL (83).
TRAIL resistant colon cancer cell lines were sensitized
for exogenously administrated TRAIL by combined exposure
with IFNγ and TNFα through down-regulation of Bcl-XL.
Evidence for a similar resistance mechanism was provided in
a murine CT26 colon carcinoma mice model. In this model,
tumor infiltrating macrophages, NK cells and T cells secreting
IFNγ and TNFα and expressing TRAIL were responsible
for suppression of lung metastases since neutralizing TRAIL
antibodies blocked antitumor activity leading to increased lung
metastases. Moreover, it was shown that adoptive transfer of
tumor-specific CD8+ CTLs producing IFNγ and TNFα together
with recombinant TRAIL/agonistic mAb therapy effectively
induced apoptosis in CT26 tumor cells in mice, whereas TRAIL
alone was ineffective, indicating cooperative activity between
tumor infiltrating immune cells and TRAIL therapy (84).
Taken together, stromal cells can produce various factors that
in a paracrine way suppress or enhance the therapeutic efficacy of
TRAIL-R agonists.
TME Remodeling
Application of exogenous TRAIL may also impact the TME by
targeting specific cellular components. In contrast to the dogma
that normal cells are refractory to the death inducing effect
of TRAIL Liguori et al. reported susceptibility of monocytes
and macrophages for TRAIL-induced apoptosis (85). In vitro,
human monocytes and macrophages expressed TRAIL-R1/R2
and underwent apoptosis after TRAIL exposure, whereas
neutrophils and lymphocytes expressing mainly decoy TRAIL-
R3 did not. Furthermore, in murine fibrosarcoma implanted
mice, TRAIL-R expressing monocytes were sensitive for TRAIL.
Interestingly, particularly infiltrating TAMs but not normal tissue
resident macrophages expressed functional TRAIL receptors.
TAMs that have protumorigenic activity in this syngeneic mouse
model were sensitive to TRAIL-induced apoptosis resulting in
significant decreases in circulating monocytes and infiltrating
TAMs and a concomitant reduction in tumor growth and
metastasis (85).
TRAIL resistant murine hepatocellular carcinoma
(HEPA-1-6) cells in vitro, became sensitive for intratumoral
injection of TRAIL after implantation in mice. Analyses of
tumor infiltrating immune cells revealed that TRAIL injections
decreased the numbers of Trail-R positive Tregs, whereas levels
of CD8+ CTLs increased. Thus, TRAIL treatment appears
to deplete Tregs by apoptosis thereby potentiating CD8+
CTLs-dependent antitumor responses, in addition to the direct
apoptotic effects on HEPA-1-6 tumors (86).
In acute myeloid leukemia HL-60 cells TRAIL triggered
apoptosis. However, in the surviving fraction an increase in
monocyte maturation markers was observed, requiring TRAIL-
R1 and caspases activation. In normal monocytes TRAIL also
was able to induce expression of CD14 and CD11b maturation
markers associated with enhanced phagocytic capacity and
antitumor activity. Accordingly, TRAIL therapy has dual anti-
neoplastic activity by directly killing tumor cells and enhancing
monocyte/macrophage activity (87).
TRAIL could stimulate the production of pro-inflammatory
cytokines IL1β, IL6, and TNFα in a NF-kB-dependent way in
human and murine macrophages in vitro. Similarly, TRAIL
was able to stimulate pro-inflammatory cytokine expression in
TAMs in tumors derived from TRAIL sensitive H460 NSCLC
cells in nude mice, but not in peritoneal macrophages that
was related to high miR-146 expression in the latter leading
to silencing of cytokine expression. Moreover, co-cultures of
H460 and TRAIL-stimulated TAMs showed that cytokines
produced by TAMs potentiate the TRAIL-dependent killing of
H460 cells (88).
Tumor vasculature has been reported to be sensitive for
TRAIL-induced apoptosis via TRAIL-R2. In different murine
tumor models tumor-associated endothelial cells expressed
TRAIL-R2 and were sensitive for the killing effect of TRAIL
resulting in tumor starvation, even when tumor cells were
TRAIL resistant. IHC demonstrated TRAIL-R2 expression
in NSCLC patient vasculature and therefore TRAIL-induced
collapse of tumor blood vessels was proposed as an alternative
or complementary therapeutic strategy (89). Another favorable
effect of TRAIL on the TME was reported by downregulating
OPG production in MSCs, fibroblasts and endothelial cells by
TRAIL-mediated inhibition of p38/MAPK activation (90).
These findings illustrate that the antitumor activity of
TRAIL can be directly enhanced by simultaneously potentiating
the antitumor effect of stromal cells or by suppressing the
protumorigenic activity of stromal cells leading to an overall
therapeutic benefit.
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Contrary to above findings, tumor cells were found to
create a protumorigenic niche involving TRAIL signaling via
indirect means. In TRAIL resistant NSCLC cells TRAIL exposure
triggered the secretion of immune-suppressive cytokines IL8,
CXCL1, CXCL5, and CCL2 in a FADD- and caspase-8-
dependent way. Particularly CCL2was found to inducemonocyte
polarization into MDSCs and generated M2 macrophages.
Orthotopic implanted TRAIL resistant A549 NSCLC andmurine
LL3 cells with FADD deleted showed reduced tumor growth
compared to implanted WT tumor cells. This was associated
with decreased cytokine production including CCL2 leading
to reduced tumor infiltration of tumor supporting monocytes
and MDSCs (91).
TRAIL treatment of resistant human pancreatic cells
resulted in enhanced invasion in vitro and metastatic spread
in orthotopically implanted nude mice. TRAIL-induced
NF-κB activation stimulated production of pro-inflammatory
cytokines IL8 and MCP1/CCL2, proteases MMP7 and MMP9
and urokinase-type plasminogen activator (uPA) that were
responsible for pro-inflammatory effects and metastatic spread
(92, 93). More recently, the chemokine CCL20 was identified
as a TRAIL/NF-κB inducible target gene in resistant pancreatic
cancer cells that indirectly modulated TRAIL resistance in mice
by recruiting peripheral blood mononuclear cells (PBMCs),
which further increased TRAIL resistance of CCL20-producing
pancreatic cancer cells (94). Thus, in pancreatic cancer TRAIL
had unfavorable effects by stimulating pro-inflammatory
cytokines production leading to enhanced metastasis and
TRAIL resistance.
A positive feedback loop between tumor cells and
macrophages was identified in promoting growth and survival
of colon cancer cells. Macrophages producing IL1β could
stimulate growth of colon cancer cells by activating GSK3β/Wnt
signaling (95). IL1β production by macrophages was induced
by tumor cells and resulted in protection of colon cancer
HCT116 cells from TRAIL-induced apoptosis. IL1β-mediated
TRAIL resistance involved activation of NF-κB and GSK3β/Wnt
pathways leading to stabilization of the EMT transcription
factor Snail (96).
TRAIL treatment was also shown to enhance pro-
inflammatory cytokine and chemokine production, including
IL6, IL8, MCP1, CXCL1, and MIF, in various cancer cell
types independent from TRAIL sensitivity although cytokines
levels were higher in resistant cancer cells. MCP1 promoted
chemotaxis of THP-1 monocytes and IL8 recruited neutrophils
that may enhance tumor growth. Mechanistic studies revealed
that caspase-8 was required for both apoptosis activation and
cytokine production, although non-cleaved procaspase-8 was
responsible for cytokine production by functioning as a scaffold
for formation of a FADD-Caspase-8-RIPK1-TAK1 signaling
complex and subsequent activation of the MEK/ERK pathway
and cytokine production (97).
Taken together, depending on the experimental model and
tumor type the overall antitumor effect of exogenous TRAIL is
modulated by paracrine effects elicited either by direct activation
of TRAIL-Rs on tumor cells or indirectly by activation of TRAIL-
Rs on stromal cells, particularly immune cells. These effects can
have either positive or negative impact on antitumor activity or
even have tumor promoting effects.
BIOCHEMICAL AND BIOPHYSICAL
PROPERTIES OF THE TME
Besides cellular compounds, the TME is also characterized by
hypoxia, increased acidity and aberrant tissue stiffness involving
alterations in ECM as well as aberrant interstitial pressure.
Consequences for TRAIL signaling are exemplified below.
The ECM
The ECM is a collection of different macromolecules that
are assembled in a three-dimensional structure with unique
biochemical and biomechanical properties regulating cell growth,
survival, motility, and differentiation. The ECM provides
cells with a scaffold and regulates hydration and pH as
well as the availability of growth factors and cytokines (98).
Cell-ECM interactions play an important role in tumor
development and maintenance, and degradation of the ECM
is associated with metastatic spread of tumor cells. ECM-
cell adhesion signaling predominantly involves interactions
between cell surface integrins and fibronectin. Genetic and
pharmacological targeting of Integrin-β and downstream signals
such as Src, Talin, PI3K, and MAPK sensitized both apoptosis
resistant and sensitive tumor cells for TRAIL-induced apoptosis
in vitro by increasing TRAIL-R leveling and reducing the
threshold for mitochondrial apoptosis (99). These findings
also provide a mechanistic rationale for adherent tumor cells
being more resistant to TRAIL than disseminating cells. On
the other hand, loss of the epithelial adhesion protein E-
cadherin, a key characteristic of cells undergoing EMT, has
been linked with TRAIL resistance. EMT induction in lung
cancer cells resulted in TRAIL resistance and silencing of E-
cadherin also inhibited apoptosis activation. Mechanistically,
E-cadherin was found to bind to ligated TRAIL-R1and/or
TRAIL-R2 and augment their clustering and coupling to the
actin cytoskeleton resulting in efficient DISC assembly and
caspase-8 activation. Although elevated levels of E-cadherin
in a panel of tumor cells correlated with TRAIL sensitivity,
ectopic overexpression of E-cadherin in TRAIL resistant
tumor cells did not lead to sensitization indicating context
dependency (100).
Other components of the ECM were also found to regulate
TRAIL sensitivity. The elastin microfibril interface-located
protein 2 (EMILIN2), a member of the family of ECM
glycoproteins, can bind to TRAIL-R1 and to a lesser extent
TRAIL-R2 to induce receptor clustering and co-localization in
lipid rafts subsequently activating apoptosis (101). The CCN
family of integrin-binding matricellular proteins have pleiotropic
functions including regulation of cell proliferation and survival.
In prostate cancer cells CCN1 was reported to support cell
adhesion via integrins and heparan sulfate proteoglycans (HSPG)
and promote growth. However, CCN1 also led to sensitization
to TRAIL-induced apoptosis that was dependent of CCN1
interations with integrins and HSPG receptor Syndecan-4 and
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activation of protein kinase C (102). Thus, the ECM can
modulate TRAIL-R functioning and affect the outcome of
TRAIL exposure.
Mechanical Stress
Tumor cells experience elevated mechanical stress as a result
from multiple factors including increased interstitial fluid
pressure by aberrant vasculatures and lack of functional
lymphatic vessels in tumors. Moreover, these cells experience
solid stress as a result of tumor cell proliferation, aberrant
ECM production, and an altered TME. Together these
factors result in enhanced mechanical stress in tumors that
has been associated with decreased efficacy of anti-cancer
treatment (103).
A limited number of studies examined the role of mechanical
stress on TRAIL sensitivity. Elevated pressure on hepatoma
Hep3B cells was reported to sensitize for TRAIL-induced
apoptosis by suppressing ERK1/2 activation resulting in
decreased Bad phosphorylation and enhanced mitochondrial
apoptosis (104). Similarly, elevated atmospheric pressure on
H460 NSCLC cells enhanced TRAIL-dependent apoptosis
associated with up-regulation of TRAIL-R2 and potentiation
of caspase-8, accompanied by enhanced c-FLIP degradation
and reduced expression of XIAP and the antiapoptotic protein
Survivin. Enhancement of TRAIL-induced apoptosis was
also detected in additional cancer cell lines, whereas normal
fibroblast remained TRAIL resistant (105). The mechanism
transmitting pressure-induced TRAIL sensitization has not been
elucidated yet.
Interestingly, in xenograft mice models TRAIL treatment
rapidly reduced interstitial fluid pressure in TRAIL sensitive
tumors, but not in TRAIL resistant ones that was accompanied
by less condensed tumors. TRAIL treatment was associated
with changes in the TME including stromal widening,
macrophage infiltration, and better vascular perfusion, which
also increased the efficacy of chemotherapy efficacy (106).
Another study in larynx carcinoma HEP2 cells showed a
correlation between stiffness and inhibition of TRAIL-induced
apoptosis. Actinomycin D treatment reduced cellular stiffness
that was linked with F-actin depolarization and susceptibility
for TRAIL dependent apoptosis involving decreased Bcl-2
expression (107).
Indirect evidence for a suppressive effect of mechanical
stress on TRAIL-mediated apoptosis was provided by Cho
et al. (108). Lung tumor stroma is enriched for fibronectin,
which is a multimodular protein able to stretch by partially
unfolding under mechanical pressure. This stress can be
experimentally mimicked by administration of recombinant
type III domain of fibronectin (FnIII-1c). FnIII-1c reduced
TRAIL sensitivity in H460 lung cancer cells. Inhibition of
TRAIL induced caspase-8-dependent apoptosis was mediated
by PI3K/Akt pathway activation via increased binding of
αvβ5 integrin to its ligand vitronectin, a plasma protein and
ECM factor (108).
Together, few studies thus far showed mostly a positive effect
of mechanical stress on TRAIL-induced apoptosis, although
clearly more research is required.
Hypoxia
Hypoxia is a common condition of the TME and has been
reported to affect TRAIL signaling by a variety of mechanisms
leading to either enhanced or reduced TRAIL sensitivity. Most
studies found that a hypoxic TME diminishes TRAIL sensitivity
by a diversity of mechanisms. For example, hypoxia could
block mitochondrial apoptosis by upregulating anti-apoptotic
proteins or downregulating pro-apoptotic members of the
BCL-2 family (109). More recently, hypoxia was shown to
stimulate mitochondrial autophagy resulting in impairment of
the mitochondrial amplification loop by reducing mitochondrial
release of pro-apoptotic factors such as SMAC. Exogenous
substitution by SMAC mimetics or inhibition of XIAP restored
TRAIL induced apoptosis under hypoxic conditions (110).
The hypoxia-inducible transcription factor HIF1α was found
to be essential for hypoxia-dependent inhibition of TRAIL-
induced apoptosis in a number of cancer cell lines in vitro
(111). Expression of the cellular prion protein (PrPc) was
shown to be enhanced by HIF1α under hypoxia and to
mediate TRAIL resistance in colon cancer cells in vitro and
in vivo and may involve enhanced Akt and Bcl-2 activity
(112). Another study linked HIF1α as a major mediator of
enhanced TRAIL-R4 production, but not other TRAIL-Rs, at
the cell surface of colon cancer cells (113). HIF2α that has
been less well-studied in context of TRAIL signaling had a
protective effect on TRAIL-induced apoptosis in most pancreatic
cancer cell lines tested by transcriptionally enhancing the
expression of antiapoptotic protein Survivin. Accordingly, the
Survivin inhibitor YM155 sensitized for TRAIL apoptosis under
hypoxia (114).
Although most studies demonstrated a decrease in TRAIL-
driven cell death under hypoxic conditions, several studies
reported pro-apoptotic activity. For example, hypoxia increased
TRAIL-induced apoptosis in DU-145 and LNCaP prostate cancer
cells accompanied by enhanced activation of caspase-8 and−3
but not caspase-9 (115). In breast cancer cells hypoxia increased
TRAIL-R2 expression via JNK and C-Jun resulting in increased
TRAIL sensitivity (116). Others found that hypoxia decreased
PKCε levels in a HIF1α dependent way leading to sensitization
for TRAIL (117). The underlying cause of the differential
effects of hypoxia on TRAIL sensitivity is unclear, but may
be related to the degree in which the cancer cell line tested
is dependent on activation of the mitochondrial amplification
loop (type-II cells).
Extracellular pH
High dependency of tumor cells on glucose to fuel aerobic
glycolysis, known as the Warburg effect, provides energy
and biosynthetic metabolites required for growth. Hypoxic
conditions favoring anaerobic glycolysis in tumor cells further
enhances the production of extracellular lactate and is a main
cause of an acidic pH in the TME (118). TRAIL was found to
induce cell death in a pH-dependent manner. At low pH (6.6)
TRAIL-induced apoptosis was augmented in prostate carcinoma
and colorectal carcinoma characterized by increased tBID/BAX
interactions, cytochrome C release and caspase activation (119).
In gastric carcinoma cells low pH resulted in upregulation of
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TRAIL-R1 and –R2 gene and protein expression and increased
proapoptotic activity of TRAIL via TRAIL-R2 (120). Others
reported that an acidic extracellular pH of 6.5 enhanced TRAIL-
induced cell death in colon carcinoma and hepatocarcinoma
cell lines by switching to activation of a caspases- and RIPK1-
dependent necroptosis (121).
Glucose
Tumor cells suffer usually from glucose deprivation and
hypoglycemic conditions, which can impact TRAIL signaling.
TRAIL sensitivity was increased in a glucose deprived
environment in a variety of cancer cell lines (122, 123). Glucose
deprivation enhanced TRAIL sensitivity by increasing DISC
formation and potentiation of mitochondrial depolarization and
cytochrome c release and subsequent caspase activation
(115, 122, 123). In addition, glucose deprivation also
increased ceramide levels leading to inhibition of Akt
and reduced cFLIP levels leading to enhanced TRAIL
sensitivity (123).
In mantle cell lymphoma cells chronic glucose deprivation
resulted in a switch from aerobic glycolysis to oxidative
phosphorylation thereby maintaining ATP production that was
accompanied by reduced sensitivity toward TRAIL induced
apoptosis. Glucose-free conditions led to decreased surface
expression levels of TRAIL-R1/R2, impaired DISC formation,
increased levels of Bcl-2 and XIAP, decreased levels of Bax
FIGURE 1 | Main interactions between tumor and cellular TME that modulate TRAIL signaling. Schematic overview of effects of cellular TME—tumor interactions on
TRAIL/TRAIL-R signaling. Green boxes depict antitumorigenic TME interactions. This can be achieved by endogenous TRAIL expression on activated immune effector
cells leading to TRAIL-R dependent apoptosis in tumor cells. TRAIL-expressing neutrophils and macrophages can also eliminate tumor cells via TRAIL-Rs and
cytokines can enhance infiltration of these cells potentiating tumor killing. Other stromal cell types expressing TRAIL may also display antitumor activity. Exogenous
recombinant TRAIL, or TRAIL-R agonistic antibodies can induce cell death in tumor cells and immune suppressive cells (TAMs, Tregs) resulting in enhanced numbers
of CTLs and increased phagocytic capacity of neutrophils/monocytes/macrophages. TRAIL-induced cell death of tumor endothelial cells has also been demonstrated
(not depicted). Exogenous TRAIL can stimulate release of cytokines able to further increase TRAIL/TRAIL-R levels on immune effector cells. Together these events
potentiate antitumor activity via the TRAIL/TRAIL-R system. Red boxes depict protumorigenic interactions. Endogenous TRAIL/TRAIL-R expression on often resistant
tumor cells can induce TRAIL-driven cell death in antitumor TILs, CTLs. Cytokines can down-regulate expression of TRAIL on immune effector and
neutrophils/macrophages. Decoy TRAIL-R3/R4 and OPG expression on stromal and tumor cells can sequester exogenously added TRAIL/TRAIL-R agonists and
protect against apoptosis. Resistant tumor cells stimulated with TRAIL secrete cytokines that recruit immune suppressive cells and/or induce a suppressive
phenotype in tumor infiltrated cells. Cytokines derived from tumor and stromal cells can increase tumor TRAIL resistance by enhancing antiapoptotic signaling or even
stimulate metastasis. Although often studied separately, it is anticipated that TME-dependent modulation of endogenous and exogenous TRAIL activity will occur
simultaneously. See text for details.
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and cytosolic cytochrome c. Conversely, 2-deoxyglucose that
inhibits glycolysis and caused a reduction in ATP levels
sensitized for TRAIL-induced apoptosis by potentiating DISC-
dependent caspase-8 apoptosis as a result of a general decrease
in mRNA translation including antiapoptotic proteins such as
cFLIP. This study indicated differences between chronic and
temporally glycolysis inhibition on TRAIL signaling likely related
to mitochondrial functioning and intrinsic apoptosis (124). In
a follow up study by the same group the balance between the
Akt and AMPK and downstream regulation of mTORC1 was
proposed to be instrumental in modulating protein translation
and the equilibrium between pro- and anti-apoptotic Bcl2 family
members (125).
Taken together, mechanical stress, hypoxia, pH, and glucose
availability all have a direct effect on tumor cell apoptosis
sensitivity for TRAIL. The impact of these conditions on stromal




To unleash the full clinical potential of TRAIL receptor agonists
we need to unravel the complexity of TRAIL signaling pathways
in order to effectively bypass apoptosis resistance. As illustrated
here, the TME plays an important role in modulating the efficacy
of both the endogenous TRAIL/TRAIL-R system mostly used by
immune cells as well as of exogenously administrated therapeutic
TRAIL receptor agonists. This modulation is complex involving
a multi-component TME and a variety of often bidirectional
signals that regulate TRAIL-driven apoptosis at distinct cellular
FIGURE 2 | Interactions between tumor and non-cellular TME that modulate TRAIL signaling. Schematic representation of the impact of tumor specific biochemical
and biophysical conditions on TRAIL/TRAIL-R signaling. Limited data available thus far indicate mostly a TRAIL sensitizing effect for mechanical stress and acidic pH,
resistance by hypoxia and both sensitizing and resistance by ECM and low glucose. Interaction of tumor cells with ECM activates antiapoptotic signaling via integrin
signaling, although conversely loss of E-cadherin has been linked with TRAIL resistance. Mechanical stress as a result of external pressure can sensitize for apoptosis
and exogenous TRAIL in apoptosis sensitive tumors can reduce interstitial fluid pressure having favorable antitumor effects. Hypoxia and low pH are mostly associated
with apoptosis resistance by stimulating antiapoptotic pathways and suppressing mitochondrial apoptosis. Glucose deprivation has been linked with both TRAIL
sensitization and resistance, likely depending on chronic or temporal glucose deprived conditions. See text for more details.
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and molecular levels. In this context the tumor model and
experimental conditions used are of key importance, giving rise
to different outcomes of TRAIL/TRAIL-R signaling, being either
tumor promoting or suppressive effects. The use of syngeneic
mouse models with a fully active immune system appear most
valuable to dissect TME-cancer interactions, although obviously
the TRAIL/TRAIL-R system in humans is not identical to that
in mice.
The cellular TME, consisting of among others immune
effector cells, immune-suppressive Tregs, neutrophils,
macrophages, and non-hematopoietic stromal cells, is able
to enhance or reduce the antitumor activity of TRAIL-
expressing immune effector cells as well as of exogenous TRAIL
(see also Figure 1). In response to TRAIL-R activation tumor
and stromal cells can initiate feed forward mechanisms or launch
a counterattack leading to suppression of antitumor activity.
Interestingly, therapeutic TRAIL can also remodel the TME by,
for example, eliminating tumor-infiltrating macrophages, Tregs,
or tumor endothelial cells resulting in additional antitumor
activity. Conversely, TRAIL-R stimulation of particularly
apoptosis resistant cancer cells can have protumorigenic effects,
illustrated by enhanced cytokine secretion and attraction of
immune suppressive cells. Although the underlying mechanisms
need further clarification, regulation of endogenous and
exogenous TRAIL sensitivity by tumor—stroma cell interactions
frequently involve regulation of TRAIL/TRAIL-R levels
including decoy receptors and OPG, and NF-κB-dependent
regulation of intracellular pro- and antiapoptotic factors such
as Bcl2 family members and IAPs together with secretion of
cytokines in feedforward or feedback loops. In some studies the
efficacy of therapeutic TRAIL could be potentiated by inhibiting
these antiapoptotic regulators. In addition, sequestering of
TRAIL by upregulation of decoy receptors can be minimized
by the use of designed recombinant TRAIL variants or
TRAIL-R1 or -R2 agonistic antibodies that have strongly
reduced binding affinity for decoy TRAIL-Rs. Furthermore, to
achieve specific targeting of selected tumor or stromal cells,
bi-functional TRAIL-R1 or -R2 agonistic antibodies or TRAIL
fusion proteins have been developed containing a cell-specific
binding moiety in addition to a TRAIL-R binding part. For
example, a bi-specific melanoma-associated chondroitin sulfate
proteoglycan (MCSP)—DR5 (TRAIL-R2) antibody has been
produced that combines high affinity binding to melanoma
cells with strong apoptosis-inducing potential (126). Similarly,
bi-specific antibodies have been developed that allow targeted
delivery of TRAIL to surface antigens of T cells to enhance
their tumoricidal activity. Moreover, bi-specific antibodies
combining PD-L1 immune checkpoint inhibition with TRAIL-
induced cell death could counteract an immune suppressive
TME and augment T cell activation (127). Notably, the small
molecule ONC201, currently evaluated in clinical studies, targets
multiple pathways in tumor cells and includes upregulation of
TRAIL and TRAIL-R2 transcription. Within tumors ONC201
prompted activation and accumulation of T-cells (CD3+,
CD4+, and CD8+) and NK cells thereby selectively potentiating
their antitumor activity that involves the TRAIL/TRAIL-R
system (128).
The impact of the non-cellular TME on TRAIL signaling in
cancer cells is less well-studied. Thus far, studies demonstrated
either TRAIL-dependent tumor suppressive or enhancing effects
of mechanical stress, hypoxia, acidic pH, and glucose shortage,
whereas effects on stromal cells have not been explored until
now (see also Figure 2). To appreciate the importance of signals
derived from these TME components and to develop targeted
strategies, it is essential to gain more insight in these poorly
studied underlying mechanisms.
To conclude, in order to improve clinical benefit of TRAIL-R
agonists the impact of various components of the TME need to
be delineated using appropriate cancer models, which will guide
the development of better therapeutic strategies.
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